Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 19 for Acute myelogenous leukemia

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study to Evaluate Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML

    Jacksonville, FL, Rochester, MN

  3. A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma

    Rochester, MN

  6. A Study to Evaluate Pevonedistat, Azacitidine, and Venetoclax (PAVE) to Treat Acute Myelogenous Leukemia (AML) Patients

    Rochester, MN

  7. PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study to Determine the Recommended Dose of CYAD-02 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients

    Jacksonville, FL

  9. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer